23andMe announces in vivo results for 23ME-01473 in Phase 1 trial

23andMe announced nonclinical data supporting the anti-tumor activity of its first-in-class 23ME-01473 antibody targeting the NKG2D ligand ULBP6 at the European Society of Medical Oncology Congress 2024 in Barcelona, September 13-17. In a poster presentation at the 2024 ESMO Congress, 23andMe Therapeutics presented new data showing that 23ME-01473 inhibits growth of non-small cell lung cancer in a patient-derived xenograft mouse model. The presentation also included data showing elevated plasma soluble and tumor expression levels of ULBP6 in squamous cell carcinomas and a subset of adenocarcinomas. These findings have led to the prioritization of four expansion cohort cancer types for potential further investigation during the Phase 2a dose expansion portion of the Phase 1/2a trial, which began in March 2024: head and neck squamous cell carcinoma, squamous non-small cell lung cancer, colorectal cancer and triple-negative breast cancer. The design of this Phase 1/2a trial was presented in a second Trials-In-Progress presentation at the ESMO Congress.